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Introduction
Pseudoexfoliation (PEX) syndrome is a daily chal-
lenge for ophthalmologists because of aggressive secondary
glaucoma and cataract surgery complications caused by its
presence. Although it has been known since the beginning
of the 20th century, the interest for its research has been in-
creasing during the last few decades. It has been found that
PEX syndrome exists in diseases of other organs and sys-
tems. In addition, the origin and nature of PEX material has
not been explained yet, which further arouses the interest of
scientists.
Discovery of pseudoexfoliation syndrome
Research of Finnish ophthalmologist John G. Lindberg
was inspired by the works of his senior colleague, the Ger-
man ophthalmologist Axenfeld, who described changes in
the iris of older people. Obeying his own research needs,
Lindberg worked on the thesis, examining the patients at the
slit lamp, which he constructed himself. Thus, he observed
and described the changes in the form grayish villi and flakes
at the pupillary edge and lens in patients with cataract older
than 50. In patients with chronic glaucoma, changes were
found in 50% of cases. In his doctoral thesis, presented in
1917 at the University of Helsinki, Lindberg described in
detail the observed changes in the iris and lens, and he per-
sonally illustrated his work.
A few years later, Lindberg gave a copy of his thesis to
his Swiss colleague A. Vogt. But Vogt published his first
work on PEX and glaucoma, not even once mentioning
Lindberg and his work. Lindberg also borrowed his thesis to
the Swedish ophthalmologist, Malling, who shortly after-
wards published papers on this subject, also without men-
tioning Lindberg and his discovery.
Lindberg received a full recognition posthumously, a
few decades later, thanks to Finnish ophthalmologists 
1. In-
terest in PEXs was awakened later, in the 80s and in 1998,
the International Association for the Study of PEX was es-
tablished, which was named after Lindberg – the Lindberg's
Society.
At first, it was thought that PEXs originated from an-
terior lens capsule [exfoliation superficialis capsule anterio-
ris (Malling, Vogt)], and then they were only deposited on
the front lens capsule (Busacca). Georgiana Dvorak-
Theobali first suggested the term PEX (1954) 
2, in order to
make the difference with the lamellar exfoliation of the lens
capsule within glass blowers 
1–3. In 1964,  Bertelsen,
Drablos and Flood found deposits located in the very lens
epithelial cells and suggested the term fibrillopathia epi-
telio-capsularis. Today, we use the term pseudoexfoliation
syndrome (PEX syndrome, PXF syndrome, XFS, PXS,
PES) and, less frequently, exfoliation syndrome and senile
lens exfoliation.
Clinical diagnosis of pseudoexfoliation syndrome
PEX syndrome is a systemic disorder of basement
membrane. Until recently, as a direct cause of disease, the
syndrome has been recognized only in the eye, where it
causes aggressive secondary glaucoma and cataract surgery
complications.
Initially, the syndrome is typically manifested unilater-
ally. However, electron microscopy indicates that subclinical
changes mostly exist in the other eye, as well. In the later
course, PEX syndrome becomes clinically manifested in both
eyes. A patient usually has no symptoms or complains about
sight quality, caused by cataract or a deficit in the visual field
due to glaucoma. The diagnosis is made by standard oph-
thalmic examinations. It is sufficient to use biomicroscopeVolumen 70, Broj 8 VOJNOSANITETSKI PREGLED Strana 763
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with slight light (sensitivity of the examination is 85% and
specificity of up to 100%) 
4. PEXs can be clearly seen on the
pupillary margin. Overview of the anterior eye segment, with
pharmacological mydriasis, recognizes “3-ring” or “eye
bull’’ sign on the front surface of the lens. It comprises a
central disc and peripheral ring covered with PEX material
and pure annular zone between them. Pure zone is probably
caused by pupillar movement, leading to removal of PEX
from the part of lens capsule and its dispersal into the envi-
ronment. Total, white cataract may make it difficult to see
this sign.
Pupilla pure dilates with the use of mydriatics. The en-
tire anterior segment of the eye is ischemic to a certain de-
gree and iris neovascularization is possible 
5, 6. PEXs are
found in the front parts of hyaloid membrane of the vitreous
body, ciliary processes, lens zonules, cornea and trabeculum.
Primarily, they are created by epithelium of ciliary body, iris
pigment epithelium and pre-equatorial lens epithelium. It is
possible that corneal endothelium, the trabecular cells and
vascular endothelium are included in the creation of PEX
material. PEX are also found in the orbit, conjunctiva, bul-
bomotors, vorticous veins, central retinal artery, optic nerve
envelopes and skin of eyelids 
7, 8.
The movements of the iris and pupillary dynamics do
not only lead to the removal of PEX from lens capsule, but
also to the pigment dispersion from the pigment layer of iris.
In this way, there are some places of iris transparency and
pupillary edge atrophy. Pigment granules accumulate in the
chamber angle. Chamber angle is intensely and inhomogene-
ous pigmented and pigmentation of the angle is most pro-
nounced in the Schwalbe’s line and in front of it (Sampaolesi
line).
Lens capsule is thin and easily and unexpectedly torn
during capsulorhexis of cataract surgery. Lens suspensory
zonules (Zinni zonules) are weakened, leading to a tendency
towards dislocation of the lens during minor trauma, and
during the operational lens extraction. Split of the lens cap-
sule, prolapsed vitreous body and lens or intraocular artificial
lens dislocation are common complications of cataract sur-
gery in subjects with the syndrome 
4, 9. Changes on the cor-
neal endothelium predispose the development of endothelial
decompensation during cataract surgery and corneal edema
during the postoperative period.
Aimed at preventing some operational complications, in
longer use are several instruments and surgical modifications
in cataract extraction, which increase comfort to an ophthal-
mologist during surgery and, to some extent, affect the inci-
dence of some early and late postoperative complications 
10.
Weak suspensory zonules allow movement forward of
the entire lens, so in some persons with PEX syndrome the
anterior chamber looks shallow and chamber angle nar-
rowed. In advanced stages of the syndrome, phacodonesis is
visible (lens shakes while moving eyes).
Cataract is frequently associated with the PEX syn-
drome 
4, 9–11. It is a mixed, cortico-nuclear type, with large,
pigmented nucleus (brunescent). The findings that PEX syn-
drome is a risk factor for age-related macular degeneration
are not consistent 
4, 12, 13.
Pseudoexfoliation glaucoma
Today, it is believed that PEX syndrome is the most
common cause of open angle glaucoma. It is expected that
up to 50% of people with PEX syndrome have elevated in-
traocular pressure. In people with PEX syndrome, intraocular
pressure is significantly higher, even when it was within
normal limits 
9, 14, 15. The risk of conversion of intraocular
hypertension to glaucoma is twice as high in patients with
PEX syndrome. In 5 years, 7%–30% of persons with PEX
syndrome will develop glaucoma 
16. Although PEX syn-
drome itself does not produce optic nerve damage, people
with diagnosed PEX syndrome should be inspected once a
year 
3, 4, 17. Sometimes, glaucoma may firstly develop in an
eye without clinically manifest PEXs 
16.
PEX glaucoma is secondary open-angle glaucoma. Ear-
lier, it was known as capsular glaucoma (glaucoma capsu-
lare). Glaucoma can manifest as closed/narrow-angle glau-
coma. Lens weakened zonules and instability of lens allow
moving forward of iridolental membrane, and thus the emer-
gence of a narrow chamber angle and shallow anterior
chamber. In addition, the pupilar bloc development is helped
by the presence of iridolental synechies and iris rigidity
within the syndrome 
3, 4.
Glaucoma is a secondary event. Blockage of the trab-
ecular spaces by PEX material promotes accumulation of
pigment and cellular debris, which causes obstruction of the
aqueous channels and limits access to the Schlemm canal.
Accumulation of PEX material in the juxtacanicular tissue
adjacent to the Schlemm canal leads to narrowing of the ca-
nal lumen, collapse of its walls, disruption of its endothe-
lium, and partial obliteration. These changes appear to be the
causative factors for chronic intraocular pressure elevation
and PEX glaucoma.
PEX glaucoma has an aggressive course and an unfa-
vourable prognosis. In its course there are high values and
large day-night variations of pressure, rapid deterioration of
nerve fibers of the retina and optic neuropathy, rapid pro-
gression and development of blindness. Eyes with primary
open-angle glaucoma (POAG) were found to have axon loss
associated with more connective tissue in the septa and sur-
rounding the central retinal vessels and a decrease in the den-
sity of capillaries as compared with eyes with PEX glaucoma
where the capillary density did not change with axon loss 
18.
Optical coherence tomography (OCT) and Heildeber retina
tomography (HRT) have been used to help in the diagnosis
and follow-up of patients with glaucoma. Both OCT and
HRT have shown a high correlation between the retinal
nerve fiber layer thickness and the visual field mean defect
during achromatic perimetry.
PEX glaucoma responds poorly to medical manage-
ment of POAG, glaucoma simplex. Glaucoma is often
unilateral, compared to POAG, and if the syndrome is
manifested bilaterally, the eye with glaucoma has a more
intense pigmentation of the chamber angle 
19. Angle pig-
mentation is positively correlated with the amount of IOP,
but not with severity of glaucoma. Pressure rise in PEX
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ous humor outflow in the trabeculum and reduced uveo-
scleral flow 
20.
Medical therapy does not lead to a long-term compen-
sation of IOP. Initially, combinations of drugs are often used
in therapy, because of the weak response to monotherapy 
21.
Myotics have worsening potential for the pupillary block de-
velopment. Argon laser trabeculoplasty shows a great initial
success, but the percentage of decompensation of pressure is
up to 50%, three years after the intervention
 22. Selective la-
ser trabeculoplasty shows a similar success, but it can be re-
peated several times, because it does not cause thermal dam-
age 
23. Trabeculectomy and other filtration penetrant and
nonpenetrant surgical procedure should be usually performed
in earlier stages of the disease than in POAG. Postoperative
complications in the form of inflammation, hypotony, and
cataract are more common than in POAG.
Differential diagnosis include POAG and pigmentary
glaucoma.
Epidemiology of PEX syndrome and PEX glaucoma
PEXs syndrome prevalence increases with age, but
shows considerable variations, depending on geography and
ethnicity. Judging from early reports, it was considered that
PEX syndrome and PEX glaucoma dominate in Scandina-
vian countries 
24. Later, analyzing the results of population
studies, it was realized that these entities existed throughout
the world. This syndrome is rarely manifested before 50, and
it is most commonly recorded with patients between 69 and
75 years. In Scandinavian countries PEX syndrome was
found in 23% of people in their seventh decade 
14.
In the same study, after a 20-year follow-up period,
Swedish authors 
14 reported that the elevated IOP was 6
times more common in people with  PEX syndrome. They
found identical incidence of glaucoma in both sexes and bi-
lateral manifestation of PEX syndrome that was initially re-
corded in one eye in 55% of persons observed for 2 decades.
During the follow-up, 25% of those patients developed glau-
coma before they were 87 years of age, and in almost 60% of
cases they had characteristics of PEX glaucoma. In the same
study, the prevalence of PEX syndrome in people who were
87 was even 61%.
On Iceland, PEX syndrome and PEX glaucoma has re-
corded annual growth of 10% in people older than 50 
25. The
syndrome has not been found in the Inuits living in the polar
regions of Canada, but has a high prevalence in the Samis,
who live on the same latitude in Europe 
26. The prevalence is
4.7% in England, 6.3% in Norway, 4.4% in Germany and
1.1% in Greece. Similar prevalence exists in India, Pakistan
(hospital studies) and in some African tribes 
3. In China,
there are only 0.4% of respondents aged between 60 and 91,
hospitalized for other diseases 
27. In USA, 6–12% cases of
open angle glaucoma seem to be PEX glaucoma and the
prevalence of PEX syndrome ranges from 0.4% to 2.7% in
different regions and racial groups, with white patients pre-
dominance 
28, 29.
In some areas, PEX syndrome and PEX glaucoma are
manifested in several generations of the same family and
suggest a genetic predisposition 
12, 28, 30. However, in differ-
ent populations examined, the findings suggest mitochon-
drial, X linked and autosomal form of inheritance 
31.
Earlier papers have reported significantly more com-
mon occurrence of PEX syndrome in women
 26. Howerever,
it has not been confirmed by authors 
12, 13 from Iceland and
Greece.
Studies on PEX syndrome have been conducted on very
diverse population and also dealt with variability in the glau-
coma definition, especially in early publications. These make
it often difficult to compare different series, even when age-
specific rates are available
 31.
Extraocular localization of pseudoexfoliations and
syndrome comorbidity
PEXs have been found in the skin, lungs, liver, heart,
kidney, gallbladder and meninges, mainly in areas containing
connective tissue 
32, 33. They are also in blood vessels in the
body, but the results documenting their frequent association
with cardiovascular diseases such as angina, hypertension
and stroke 
33–36 or abdominal aortic aneurysm 
37, are contra-
dicted by the results of researchers who have found similar
frequency in the clinical syndrome and control group 
38–41. A
greater number of studies with the same design, clinical and
control subjects and methods of analysis are required for
more consistent conclusion. Cardiac arrhythmia is the most
common finding in patients with this syndrome 
41. Systemic
vascular endothelial dysfunction has been found in persons
with PEX syndrome and PEX glaucoma 
42.
PEX syndrome is often associated with Alzheimer's
disease 
43, 45. Due to similarities in the pathogenesis, some
authors call pseudoexfoliation glaucoma “eye Alzheimer's
disease”. However, the syndrome does not result in an in-
creased rate of mortality from cerebrovascular disease 
40, 41.
Quality testing of cerebral blood flow in patients with PEX
glaucoma shows a reduced speed and increased resis-
tance 
46, and magnetic resonance imaging test is periven-
tricular zone of damage, regardless of optic neuropathy in
patients who have not only PEX syndrome, but also PEX
glaucoma 
47, 48.
Hearing disorders have also been detected in patients
with this syndrome, especially in hearing the frequency
range of human voice 
49.
PEX syndrome is rare in patients with diabetic reti-
nopathy 
50 yet initiated a series of new tests. However, better
selection of groups of respondents, particularly in relation to
age, has showed that diabetes is not rare in patients with this
syndrome 
41, 42 or even that it is more common 
50.
Origin and composition of pseudoexfoliation
material
Today, the accepted concept suggests that PEX syn-
drome is a pathological process of the extracellular matrix,
which is characterized by the excessive production of ab-
normal extracellular material aggregating and accumulat-
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characteristics of PEX material, PEX syndrome is one of
the systemic elastosis that primarily affects elastic microfi-
briles 
51.
PEX material belongs to glycoprotein or proteoglycan.
It consists of a protein core surrounded by a mass of conju-
gated complex sugars. It contains glycosaminoglycans
(heparan sulfate, chondroitin sulfate, dermatan sulfate and
hyaluron acid), as well as many components of noncolagen
ingredients basement membrane and elastic microfibrile
(elastin, vitronectin, amyloid P, laminin, nidogen, fibrillin 1,
latent TGF binding protein 1  and 2, microfibrille assosciated
glycoprotein 
21. It is not known which are integral parts of
molecules and which are adhered. Human natural killer 1
carbohydrate component is considered to be responsible for
the adhesive nature of PEX. The components are connected
among themselves by enzymes and they stabilize the com-
plex. Proteolytic imbalance observed in syndrome may be
caused by a disturbed relationship between matrix metallo-
proteinases and their tissue inhibitors
 31. Because of similari-
ties in the painting composition, PEX material is often de-
scribed as amyloid 
4, 31, 32.
The origin of syndromes is associated with different risk
factors. In addition to these age and genetic predisposition,
other factors with potential cumulative but mutually dependent
effects are also mentioned: ultraviolet radiation, oxidative
stress, chronic inflammation in the autoimmune process, in-
fections caused by herpes viruses, hepatitis C virus and Heli-
cobacter pylori bacteria, as well as diet habits 
4, 25, 30, 52–57.
Hyperhomocysteinemia has been found in persons with
PEX syndrome and PEX glaucoma 
29, 51, 58. Genetic polymor-
phism lysil oxidase like 1 gene and its homozygous presence
represent the risk for the disorder of homocysteine metabo-
lism, abnormal hepatic fibrosis and aggregation of elastic
components of PEX, especially in a disturbed folate status in
the body. Similar disturbances in the plasma levels of homo-
cysteine, folic acid and vitamins B6 and B12 are evident
with Alzheimer's disease and certain cardiovascular diseases.
However, hyperhomocysteinemia exsists in patients with
POAG and normotensive glaucoma.
Elevated serum levels of connective tissue growth fac-
tor in a number of diseases accompanied by fibrosis has been
detected in patients with PEX syndrome 
57. Again, matrix
metalloproteinases are involved in its regulation. Trasform-
ing growth factor ȕ1, as a regulator of most genes that are
expressed in PEX syndrome, is increased in aqueous humor
of patients with this syndrome and is considered to be one of
the key mediators in the fibrotic process syndrome 
59.
The system of production and accumulation of PEX
makes it complex and interdependent set of elements of such
a specific, stress-induced elastosis 
31.
Conclusion
Considering population aging worldwide, including our
country, we can expect an increasing prevalence of PEX
syndrome and PEX glaucoma. Although there is no clear
pathogenesis, since the first PEX glaucoma is prevalent
among other types of secondary open angle glaucoma, it
should be studied during the regular medical studies.
Diseases mentioned in comorbidity of syndrome, which
include the risk of mortality and disability with a significant
reduction in quality of life, can be suspected earlier if the
ophthalmologic overview of the anterior eye segment is
done. The possibility of preventing such diseases or reducing
their progression is the chance that should be taken. Further
studies PEX syndrome origin and nature may help in shed-
ding light on its etiology and pathogenesis, which may open
new perspectives in its prevention.
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